Patents Assigned to Anavex Life Sciences Corp.
  • A2-73 as a therapeutic for insomnia, anxiety and agitation
    Patent number: 12285403
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Grant
    Filed: October 9, 2023
    Date of Patent: April 29, 2025
    Assignee: Anavex Life Sciences, Corp.
    Inventor: Christopher U. Missling
  • Sigma-1 receptor agonist systolic blood pressure therapy
    Patent number: 12280034
    Abstract: A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: April 22, 2025
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • TREATMENT OF CARDIAC DYSFUNCTION
    Publication number: 20250064772
    Abstract: A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof.
    Type: Application
    Filed: November 8, 2024
    Publication date: February 27, 2025
    Applicant: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Enantiomers of A2-73, analogues, and sigma agonist activity
    Patent number: 12208079
    Abstract: A pharmaceutical preparation comprising ?A2-73 substantially free of A2-73. This invention further includes a method treating Alzeheimer's disease in a subject in need of such treatment by the method of administering a therapeutically effective amount of ?A2-73 substantially free of A2-73. This invention yet further includes a method of classifying cells as to sigma receptor type by the method of exposing said cells to a detectable amount of ?A2-73 substantially free of A2-73 and determining the level of sigma receptor binding.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: January 28, 2025
    Assignee: Anavex Life Sciences Corp.
    Inventor: Gervais Neliat
  • A2-73 crystalline polymorph compositions of matter and methods of use thereof
    Patent number: 12180174
    Abstract: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: December 31, 2024
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Alani Selvey
  • Treatment of cardiac dysfunction
    Patent number: 12138240
    Abstract: A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: November 12, 2024
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • NEURODEVELOPMENTAL DISORDER THERAPY
    Publication number: 20240066003
    Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Application
    Filed: October 30, 2023
    Publication date: February 29, 2024
    Applicant: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
    Patent number: 11896590
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: February 13, 2024
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • Neurodevelopmental disorder therapy
    Patent number: 11839600
    Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 12, 2023
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • A2-73 as a therapeutic for insomnia, anxiety, and agitation
    Patent number: 11813242
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: November 14, 2023
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy
    Publication number: 20230301961
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 28, 2023
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
    Patent number: 11690821
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: July 4, 2023
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
    Patent number: 11661405
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: May 30, 2023
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York, Alani Selvey
  • A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF
    Publication number: 20230142424
    Abstract: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.
    Type: Application
    Filed: November 1, 2022
    Publication date: May 11, 2023
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. MISSLING, Alani SELVEY
  • Sigma-1 receptor agonist systolic blood pressure therapy
    Patent number: 11622955
    Abstract: A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: April 11, 2023
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY
    Publication number: 20230071766
    Abstract: A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
    Type: Application
    Filed: November 14, 2022
    Publication date: March 9, 2023
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. MISSLING
  • A2-73 crystalline polymorph compositions of matter and methods of use thereof
    Patent number: 11498908
    Abstract: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 15, 2022
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Alani Selvey
  • Neurodevelopmental disorder therapy
    Patent number: 11446275
    Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: September 20, 2022
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS
    Publication number: 20220249427
    Abstract: The present invention provides methods for treating a genetic neurodevelopmental disorder such as Rett syndrome, comprising administering to a subject in need thereof a liquid oral dosage formulation comprising a therapeutically effective amount of ANAVEX2-73.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 11, 2022
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Alani Selvey
  • OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT
    Publication number: 20220226278
    Abstract: The present disclosure provides genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy. Also described is use of the polymorphisms to personalize treatment for subjects in need of Sigma-1 receptor therapy such as treatment of neurodevelopmental and neurodegenerative diseases and conditions.
    Type: Application
    Filed: May 20, 2019
    Publication date: July 21, 2022
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. MISSLING, Mohammad Michel AFSHAR, Frédéric PARMENTIER